- Filter by
- Categories
- Tags
- Authors
- Show all
- All
- Allergy&Clinical Immunology
- Anesthesiology
- Business of Medicine
- Cardiology
- Critical Care
- Dental&Oral Health
- Dermatology
- Diabetes&Endocrinology
- Emergency Medicine
- Family Medicine/Primary Care
- Gastroenterology
- General Surgery
- Hematology-Oncology
- HIV/AIDS
- Hospital Medicine
- Infectious Diseases
- Internal Medicine
- Med Students
- Medscape Today
- Nephrology
- Neurology&Neurosurgery
- News
- News Alert
- None
- Nursing
- Ob/Gyn&Women's Health
- Ophthalmology
- Orthopaedics
- Pathology&Lab Medicine
- Pediatrics
- Pharmacist
- Plastic Surgery&Aesthetic Medicine
- Psychiatry
- Public Health&Prevention
- Pulmonary Medicine
- Radiology
- Rheumatology
- Transplantation
- Urology
October 3, 2022
Published by Med Search on October 3, 2022
Categories
Generic drug user fees make it possible for FDA and industry to continue to ensure that the American public has access to safe, effective and high-quality […]
October 3, 2022
Published by Med Search on October 3, 2022
Categories
What’s New GDUFA III enhancements for Type II API DMFs start on 10/1/2022 Drug master files (DMFs) are submissions to FDA used to provide confidential, detailed […]
October 3, 2022
Published by Med Search on October 3, 2022
Categories
Q: What is the Rare Disease Endpoint Advancement (RDEA) pilot program? A: The RDEA Pilot Program is a U.S. Food and Drug Administration pilot meeting program, […]
October 3, 2022
Published by Med Search on October 3, 2022
Categories
To promote accountability and transparency, GDUFA III includes provisions so that industry and public stakeholders are able to observe how the Agency’s fee revenues are being utilized. Financial Reports […]
October 3, 2022
Published by Med Search on October 3, 2022
Categories
FDA has completed several commitments under the terms of the Generic Drug User Fee Amendments of 2017 (GDUFA II) commitment letter to provide greater transparency regarding […]
October 3, 2022
Published by Med Search on October 3, 2022
Categories
Effective communication among ANDA applicants, DMF holders, and FDA is essential for reducing the likelihood of potential problems that could delay approvals. The reauthorization of the […]
October 3, 2022
Published by Med Search on October 3, 2022
Categories
Controlled correspondence is a correspondence submitted to FDA by or on behalf of a generic drug manufacturer or related industry requesting information on a specific element […]
October 3, 2022
Published by Med Search on October 3, 2022
Categories
GDUFA III includes several enhancements to the abbreviated new drug application (ANDA) assessment process to maximize the efficiency and utility of each assessment cycle. These enhancements […]
October 3, 2022
Published by Med Search on October 3, 2022
Categories
The Pre-Abbreviated New Drug Application (Pre-ANDA) Program is designed to assist prospective generic drug applicants in developing more complete submissions, promote a more efficient and effective […]
Prev page
123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140
Next page